Vanguard Group Inc Celularity Inc Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.17 - $0.33 $43,903 - $85,223	258,253 Added 7.43%	3,733,206 $933,000
Q3 2023 Nov 14, 2023	BUY	$0.22 - $0.56 $195,505 - $497,650	888,662 Added 34.36%	3,474,953 $764,000
Q2 2023 Aug 14, 2023	SELL	$0.42 - $0.81 $162,742 - $313,861	-387,483 Reduced 13.03%	2,586,291 $1.37 Million
Q1 2023 May 15, 2023	SELL	$0.56 - $1.15 $5,236 - $10,753	-9,351 Reduced 0.31%	2,973,774 $1.84 Million
Q4 2022 Feb 10, 2023	SELL	$1.08 - $2.35 $2,883 - $6,274	-2,670 Reduced 0.09%	2,983,125 $3.85 Million
Q3 2022 Nov 14, 2022	BUY	$0.43 - $4.31 $504,347 - $5.06 Million	1,172,900 Added 64.7%	2,985,795 $6.9 Million
Q2 2022 Aug 12, 2022	BUY	$2.81 - $12.91 $5.09 Million - $23.4 Million	1,812,895 New	1,812,895 $6.16 Million

16M

Ticker CELU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,424,000
Market Cap $269M
Description
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-de...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.